0001193125-16-759484.txt : 20161104 0001193125-16-759484.hdr.sgml : 20161104 20161104063102 ACCESSION NUMBER: 0001193125-16-759484 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20161101 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20161104 DATE AS OF CHANGE: 20161104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 161973561 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 8-K 1 d280454d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1, 2016

Commission File Number: 0-24260

 

 

 

LOGO

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   11-3131700

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 1, 2016, the Board of Directors of Amedisys, Inc. (the “Company”) appointed Christopher Gerard as the Company’s Chief Operating Officer, effective as of January 3, 2017.

Mr. Gerard, 49, previously served as President for the South Central Region of Kindred at Home, a division of Kindred Healthcare, Inc., a healthcare services company, from 2015 to 2016. Prior to his role as Regional President, Mr. Gerard was the Chief Operating Officer at Kindred at Home from 2014 to 2015. Mr. Gerard joined Kindred in 2012 as Regional Vice President when Kindred acquired IntegraCare Holdings, Inc., a home health, hospice and community care agency based in Grapevine, Texas. Mr. Gerard was an original founder of IntegraCare in 1998 and served as its President and Chief Executive Officer from 2007 to 2012.

Mr. Gerard will participate in the Amedisys Holding, L.L.C. Severance Plan for Key Executives dated April 30, 2015, as amended. Mr. Gerard does not have a family relationship with any of the current officers or directors of the Company. There is no currently proposed transaction, and since the beginning of fiscal year 2015 there has not been any transaction, involving the Company and Mr. Gerard which was a related person transaction within the meaning of Item 404(a) of Regulation S-K.

On November 3, 2016, the Company and Daniel P. McCoy mutually agreed that Mr. McCoy will continue to serve as the Company’s Chief Operating Officer until January 3, 2017.

 

Item 7.01. Regulation FD Disclosure.

On November 4, 2016, the Company issued a press release announcing the appointment of Mr. Gerard as the Company’s Chief Operating Officer, effective January 3, 2017, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.


Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number

  

Description

99.1    Press Release dated November 4, 2016


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AMEDISYS, INC.
By:  

/s/ Paul B. Kusserow

Paul B. Kusserow
President and Chief Executive Officer
DATE: November 4, 2016


EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press Release dated November 4, 2016
EX-99.1 2 d280454dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO  

Contact:

 

 

Kendra Kimmons

Managing Director of Communications

225-299-3708

kendra.kimmons@amedisys.com

Amedisys Brings In Christopher Gerard As New Chief Operating Officer

BATON ROUGE, La., November 4, 2016 – Amedisys, Inc. (NASDAQ: AMED), a leading home health, hospice and personal care company, announced today that industry leader Christopher Gerard will join the Company as Chief Operating Officer (COO) on January 3, 2017. Daniel McCoy will remain in this role until January 3, 2017.

Gerard brings more than 20 years of home health and hospice experience to the Company. In his new role, Gerard will be responsible for the Amedisys’ home health, hospice and personal care operations.

“Chris has built an impressive track record of strategic, operational and financial accomplishments over the past two decades,” said Amedisys President and Chief Executive Officer Paul Kusserow. “He has proven to be a successful and trusted leader, and his wealth of healthcare industry experience will be a valuable asset as we continue to accelerate growth. I am very pleased to have him join our executive team.”

Gerard was co-founder, President and Chief Executive Officer of IntegraCare Home Health, where he took a single home health start-up location and grew it into 54 branches, generating $71 million in annual revenues. He successfully sold the company to Kindred Healthcare (KND) in 2012.

He served as Vice President of South Central Region for the Kindred at Home division, currently a $2.5 billion home health, hospice and community care services business with approximately 700 locations and 42,000 employees nationwide. In this role, he facilitated the integration of IntegraCare; successfully negotiated, closed and integrated four other acquisitions; and oversaw 58 home health and hospice locations with annual revenues of $80 million and a staff of 1,100, including Division Vice President of Finance, Division Vice President of Operations, and Division Vice President of Sales.

Gerard was then promoted to Chief Operating Officer at Kindred at Home, where he was responsible for integrating a $140 million home health company; standardizing processes across a division involving 187 locations, staff of 3,300 and revenue of $360 million. In this role, he improved gross margin profit and EBITDA year over year; reduced operating expenses; and boosted productivity of sales team.


Most recently, Gerard served as President for the South Central Region of Kindred at Home. In this role, Gerard was responsible for the day-to-day operations, including the integration of the Gentiva Home Health acquisition within his region, the oversight of clinical excellence, financial performance and operational efficiencies for 153 home health and hospice locations in six states with annual revenue in excess of $400 million.

Gerard received his Bachelor degree in Finance from Texas Tech University.

About Amedisys

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 340,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

#    #    #

GRAPHIC 3 g280454i1.jpg GRAPHIC begin 644 g280454i1.jpg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end GRAPHIC 4 g280454i2.jpg GRAPHIC begin 644 g280454i2.jpg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